Clinical Trials Logo

Filter by:
NCT ID: NCT03839277 Suspended - Clinical trials for Colorectal Neoplasms

Adenoma Detection Rate Using Endocuff Vision in China

SinoEVADR
Start date: June 12, 2019
Phase: N/A
Study type: Interventional

The primary aim of this study is - to explore the usefulness of Endocuff Vision in colonoscopy on adenoma detection rate (ADR). Other aims include to explore the data below when Endocuff Vision is used. Mean adenomas detected per procedure, MAP Proximal Adenoma detection rate, pADR Polyp detection rate, PDR Proximal polyp detection rate, pPDR Mean polyps detected per procedure, MPP Withdrawal time, WT Cecal intubation rate, CIR Cecal intubation time, CIT

NCT ID: NCT03816852 Suspended - Clinical trials for Premature Ovarian Failure

The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Evaluate the safety of human umbilical cord mesenchymal stem cells (hucMSCs) in POI treatment; Evaluate the effective hucMSCs in POI treatment. Compare different infusion mode, meanwhile compare with hormone replacement therapy (HRT) withdrawal, so that assessing the stem cell therapy.

NCT ID: NCT03779100 Suspended - Clinical trials for Intrahepatic Cholangiocarcinoma

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Start date: December 17, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.

NCT ID: NCT03777579 Suspended - Clinical trials for Triple Negative Breast Cancer

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

This multicenter, randomized, double-blind study will evaluate the efficacy, safety of JS001 administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel as first-line therapy in participants with primarily diagnosed stage IV and recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

NCT ID: NCT03752541 Suspended - Multiple Myeloma Clinical Trials

Efficacy and Safety Evaluation of BCMA-UCART

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

NCT ID: NCT03743428 Suspended - Clinical trials for Colorectal Neoplasms

Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

BABST-C
Start date: October 22, 2020
Phase: N/A
Study type: Interventional

Bevacizumab, an antibody against vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens has been approved in the 1st and 2nd line treatments for metastatic colorectal cancers(mCRC). Other inhibitors of the VEGF pathway, such as Ramucirumab and Aflibercept are also approved in the 2nd line therapy. Apatinib is a small molecule tyrosine kinase inhibitor (TKI), which can highly selectively bind to and strongly block VEGF receptor 2 (VEGFR - 2), resulting in reduced cell migration, proliferation, and tumor microvascular density mediated by VEGF . In this study, the patients who have progressed following or on the first-line oxaliplatin and fluorouracil(5-FU) combined with bevacizumab are randomised into two arms(FOLFIRI plus apatinib or FOLFIRI plus bevacizumab) in the 2nd line setting. To identify specific biomarkers at the genetic and proteomic levels between two arms is the primary end point.

NCT ID: NCT03722186 Suspended - Lymphoma Clinical Trials

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Start date: November 13, 2018
Phase: Phase 1
Study type: Interventional

SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. The study drug will be administered by intravenous infusion.

NCT ID: NCT03629483 Suspended - Elderly Clinical Trials

Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block

Start date: December 10, 2018
Phase: Phase 4
Study type: Interventional

Delirium is common in the elderly after orthopedic surgery and is associated with worse outcomes. Continuous femoral nerve block is frequently used for postoperative analgesia after total knee arthoplasty. The investigators hypothesize that dexmedetomidine, when combined with ropivacaine for continuous femoral nerve block, can reduce the incidence of delirium and improve the long-term outcome in elderly patients after total knee arthroplasty.

NCT ID: NCT03467776 Suspended - Asthma Clinical Trials

Bronchial Dilation Test in Wheezy Infants

Start date: July 2018
Phase: N/A
Study type: Observational

The purpose of the study is to establish the methodology of bronchial dilation test by salbutamol MDI with Spacer in wheezy infants with asthma and to evaluate the effects of atopy on the exacerbation of wheeze in wheezy infants.

NCT ID: NCT03434366 Suspended - Clinical trials for Autism Spectrum Disorder

Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder

Start date: January 20, 2018
Phase: Phase 2
Study type: Interventional

Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by qualitative abnormalities in reciprocal social interactions and patterns of communication, and by a restricted, stereotyped, repetitive repertoire of interests and activities. The use of medications in adolescents and young adults with ASD is extremely common. However, few data address the effectiveness and harms of medications specifically in this population. The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.